Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 8 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Seattle Children'S Hospital Dba Seattle Children'S Research Institute has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to PAULUS, ERIN VIRGINIA, who is the busiest examiner for the company. The portfolio involves 1 distinct examiner and 1 distinct art unit.
The prosecution is currently limited to a single matter. Practitioners should focus on the specific examiner's tendencies within the 1 distinct art unit to achieve a favorable outcome.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (36%) |
| §112 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 2 | 38.0% | +52.6% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
| GRABER, JAMES J | 1 | 46.7% | +57.7% |
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| SUNSHINE, HANNAH LOUISE | 1 | 62.5% | +24.9% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| PYLA, EVELYN Y | 1 | 55.7% | +47.1% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 14d |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | SUNSHINE, HANNAH LOUISE | 28d |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 71d |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 157d overdue |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 147d overdue |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 16d overdue |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 14d |
| 17811685 | LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID | PYLA, EVELYN Y | 27d |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | SUNSHINE, HANNAH LOUISE | 28d |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 71d |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1674 | 1 |
| 1645 | 1 |
| 1656 | 1 |
| 1636 | 1 |
| 1647 | 1 |
| 1641 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | CARTER, SANDRA DILLAHUNT | 1674 | §103 | Final Rejection | — | Pending | Sep 09, 2024 |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | 1631 | §102§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 1631 | §103DP | Non-Final OA | 157d overdue | Pending | Jun 16, 2023 |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112Other | Non-Final OA | 14d | Pending | Jun 05, 2023 |
| 18030476 | METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | HUDSON, AMY ROSE | 1636 | §102§103 | Final Rejection | 71d | Pending | Dec 21, 2022 |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | SUNSHINE, HANNAH LOUISE | 1647 | §103§112 | Non-Final OA | 28d | Pending | Dec 01, 2022 |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 1641 | DP | Final Rejection | 16d overdue | Pending | Sep 12, 2022 |
| 17811685 | LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | 27d | Pending | Jul 11, 2022 |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | 147d overdue | Pending | Jul 19, 2021 |
| 16605740 | OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY | NGUYEN, QUANG | 1631 | §112 | Final Rejection | — | Pending | Oct 16, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial